Umoja Biopharma

Umoja Biopharma focuses on immunotherapy by reprogramming T cells in the body to target and destroy cancer cells. Unlike traditional methods that modify cells outside the body, Umoja's approach modifies the immune system in vivo, aiming for long-lasting remissions. The company primarily targets patients with solid tumors and hematological cancers that have not responded to other treatments. Its business model is based on developing and commercializing a proprietary CAR T-cell gene therapy platform that is scalable and can treat cancers at various stages. By producing off-the-shelf therapies in-house, Umoja can distribute its treatments more efficiently than those requiring individual customization. The goal is to enhance cancer treatment through effective use of the immune system.